Patents by Inventor Hirofumi Hirao

Hirofumi Hirao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSTIC AGENT AND MEDICINE COMPRISING ADAMTS13 AS MAIN INGREDIENT
    Publication number: 20240159751
    Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.
    Type: Application
    Filed: November 20, 2023
    Publication date: May 16, 2024
    Applicants: Kyoto University, KM Biologics Co., Ltd.
    Inventors: Koichiro HATA, Shinji Uemoto, Hirofumi Hirao, Toyonari Kubota
  • DIAGNOSTIC AGENT AND MEDICINE COMPRISING ADAMTS13 AS MAIN INGREDIENT
    Publication number: 20230168251
    Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.
    Type: Application
    Filed: December 6, 2022
    Publication date: June 1, 2023
    Applicants: KYOTO UNIVERSITY, KM BIOLOGICS CO., LTD.
    Inventors: Koichiro HATA, Shinji UEMOTO, Hirofumi HIRAO, Toyonari KUBOTA
  • Diagnostic agent and medicine comprising ADAMTS13 as main ingredient
    Patent number: 11567080
    Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 31, 2023
    Assignees: KYOTO UNIVERSITY, KM BIOLOGICS CO., LTD.
    Inventors: Koichiro Hata, Shinji Uemoto, Hirofumi Hirao, Toyonari Kubota
  • DIAGNOSTIC AGENT AND MEDICINE COMPRISING ADAMTS13 AS MAIN INGREDIENT
    Publication number: 20200284793
    Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.
    Type: Application
    Filed: January 6, 2017
    Publication date: September 10, 2020
    Applicants: Kyoto University, KM BIOLOGICS CO., LTD.
    Inventors: Koichiro HATA, Shinji UEMOTO, Hirofumi HIRAO, Toyonari KUBOTA
  • Case for storing and dispensing edible films
    Patent number: D371723
    Type: Grant
    Filed: July 24, 1995
    Date of Patent: July 16, 1996
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventor: Hirofumi Hirao